"Pharmaceutical Speed Reading Society" AbbVie terminated two cooperations the first proposed breakthrough treatment varieties publicly announced.

August 5, 2020 / Pharmaceutical Information List: Tianshili terminated the introduction of Takara products C-REV; Novarhua CAR-T cell therapy Phase 2 clinical results were positive; legendary bioCAR-T therapy is to be included in breakthrough treatment varieties; Reding Pharmaceutical Ripteni TreatmentIST was included in the National Drug Administration's priority review; Kangchen Pharmaceuticals LaRos dispersal tablet application for listing ... Daily fresh medicine news, quick reading with you to pay attention to! Part 1 Policy Briefing Update! A number of key monitoring varieties of minimum price reduction of 30%3, Wuhan City Pharmaceutical Andy Joint Mining Office issued the "Wuhan City 2020 key monitoring reasonable drug bargaining regulations" and "focus on monitoring reasonable drug bargaining drug catalog" notice.
the bargaining rules point out that the key monitoring varieties on the basis of the lowest price, at least 30% reduction.
(Wuhan Pharmaceutical Joint Mining Office) Part 2 after observation of Tian shili to terminate the introduction of Takara products C-REV Tiansli 4 announced that the company has reached a consensus with Japan's Takara company, decided to terminate the treatment of pancreatic cancer and melanoma sol tumor virus products (C-REV) related cooperation and signed a termination agreement.
(Sina Pharmaceutical News) abandoned a $134 million advance AbbVie to terminate two antibody research and development cooperation 3 days, Voyager announced that the Tau protein and alpha-synth nucleoprotein carrier antibody cooperation with AbbVie has been terminated (for reasons not disclosed).
Voyager will reserve full rights to vectorization technology and new vector expression antibodies developed in cooperation.
shares fell 12 per cent in pre-market trading and continued to fall nearly 9 per cent after the opening, helped by the collapse of the partnership.
(Sina Pharmaceutical News) $377 million AstraZenewan has won an exclusive interest in a new antifibrosis therapy on April 4 local time, Redx and AstraZenein signed a major transfer agreement for the Wnt signaling pathpupine protein inhibitor RXC006.
astraZenemon will have an exclusive license from RXC006 for the development and commercialization of fibrosis diseases such as autological pulmonary fibrosis, and will pay an early milestone payment of $17 million prior to the success of Phase 1 clinical studies.
addition, Redx is eligible for an additional $360 million in development, regulatory and commercial milestone payments from AstraZenein on the premise of successfully reaching the milestone.
(Sina Pharmaceutical News) 870 million U.S. $870 million Mercer Dong was granted exclusive license by Hanmei GLP-1R/GCGR dual agitants 4 days, MercerTon announced an exclusive license agreement with Hanmei, the latter in the research of the drug efinopegdutide treatment of non-alcoholic fatty hepatitis development, production and commercial rights.
Under the terms of the agreement, Mercado will receive exclusive development, production and commercialization interests in the U.S. and around the world, and Hanmei will receive an advance payment of $10 million and be eligible for milestone payments of up to $860 million and double-digit sales credits.
(Pharmaceutical Rubik's Cube) Part 3 Drug News Novarte CAR-T Cell Therapy Phase 2 Clinical Results Positive Novarte announced today that its CAR-T cell therapy Kymriah has obtained positive results in Phase 2 clinical trials for patients with recurrent/incurable follicular lymphoma.
-term analysis showed that the global study had reached the main endpoint of the full mitigation rate assessed by the Independent Review Commission.
(Drug Mingkangde) Run new biological class 1 innovative drugs to complete the first clinical case of glioma brain glioma 2 patients to drug Run new biology announced that the company in the study of new drug RX108 treatment of recurrent glioblastoma Phase 2 clinical research recently completed the first patient administration in Fudan University affiliated Huashan Hospital.
RX108 is a class of innovative drugs with global intellectual property rights independently developed by Runxin Bio, is a novel Na-/K-ATP enzyme inhibitor, with a "one-target multi-point" mechanism of action, through a variety of ways to play an anti-tumor role.
(Pharmaceutical Mission) GlaxoSmithKlin in the study of class 1 therapeutic biological products ICOS receptor agitant domestic clinical report 4, CDE official website shows that GlaxoSmithKlin in the study of class 1 therapeutic biological products ICOS receptor agitant GSK3359609 injections submitted a new clinical application, has been accepted.
so far, no similar target drugs have been approved for market, GSK3359609 has been in the global phase III clinical stage, is the fastest development of similar drugs in the development of new drugs.
(CDE) Legendary BioCAR-T therapy is to be included in the breakthrough treatment variety CDE official website announced the first proposed breakthrough treatment varieties, for the Nanjing Legendary Bio's LCAR-B38M CAR-T cell self-introfusion agent.
this is the first update to the "Breakthrough Treatment Publicity" column since the State Drug Administration released the Breakthrough Treatment Drug Review Procedure (Trial) on July 8.
(CDE) North China Pharmaceutical Recombinant Human Source Anti-Rabies Virus Mono-Listing Application is to be included in the priority review CDE website information shows that North China Pharmaceutical's recombinant Human-sourced Anti-Rabies Anti-Injection Application was included in the proposed priority review list on August 5, citing "clinically urgently needed shortages of drugs, innovative and improved new drugs for diseases such as major infectious and rare diseases".
(CDE) Kangchen Pharmaceuticals Laros dispersal tablets application for listing recently, Kangchen Pharmaceutical generic products De LaRos dispersal tablets listing applications received by the State Drug Administration, according to the new registration classification 4 categories to submit a declaration.
the original research manufacturer of LaRoss dispersed tablets for Novarro, the product has been approved for domestic listing since June 2010.
(Pharmaceutical Rubik's Cube) Pfizer "injection cephalosporine" was not approved in China the State Drug Administration issued a drug notice on the 3rd to receive information shows that Pfizer injection cephalosporine was not approved in China, may be actively withdrawn for enterprises, not approved or other reasons.
cephalosporine is a fifth-generation antibiotic and is clinically used primarily to treat acute bacterial skin/skin structure infections and community-obtained bacterial pneumonia.
(Pharmaceutical Rubik's Cube) Tiantian Bio-Etan Growth Hormone Phase 3 registered clinical application was accepted 4 days, Tiantian Bio announced that the State Drug Administration has accepted its Etan Growth Hormone differentiated long-term recombinant human-sourced growth hormone Phase 3 registered clinical trial application.
the trial took a weekly approach to clinical treatment of children with growth hormone deficiency in children.
(Pharmaceutical Mission) Reding Pharmaceutical Ripteni Treatment GIST was included in the priority review by the State Drug Administration Reding Pharmaceuticals recently announced that the State Drug Administration has granted KIT/PDGFR alpha kinase inhibitor Riptinyl new drugs to apply for priority review of the market qualification, the drug used to treat patients who have received treatment for three or more kinase inhibitors, including Imatini, advanced gastrointestinal mesothelioma (GIST) patients.
(Biological Valley) Tiansli depression new drug JS1-1-01 tablets approved by clinical trials, Tian Shili issued a notice that the company received approval from the State Drug Administration for the treatment of depression, the new drug JS1-1-01 drug "drug clinical trial approval notice", and will be in the near future clinical trials.
(Tian Shili Announcement) Step Pharmaceutical Subsidiary Pharmaceuticals officially launched Phase III Clinical Trial Step Pharma announced that the company's wholly-owned subsidiary Shandong Danhong Pharmaceutical developed the "recombinant anti-tumor necrotizer-alpha all-human source monoclonal antibody injection" through the Third Hospital of Zhongshan University Medical Ethics Committee clinical trial ethics approval, access to ethical review approval, the official launch of Phase III clinical trials.
project code: BC002.
Pharmaceuticals (Step Pharma Announcement) Cornerstone Pharmaceuticals Co., Ltd. in the research of drug apothyni was conditional approval by CHMP recommended cornerstone pharmaceutical partner Blueprint Medicines recently announced that CHMP issued a positive review opinion, recommended conditional approval Apotheni tablets are listed as a single-drug therapy for the treatment of adults with non-excisible or metastatic gastrointestinal mesothelioma with a plate plate plate plate-derived growth factor receptor alpha gene exon 18 D842V mutation.
the European Union approved the listing of Hepcludex's liver contosis, MYR Pharmaceuticals announced that the European Commission had granted its pilot drug Hepcludex conditional marketing authorization in the European Union.
Hepcludex is the first approved treatment for chronic hepatitis odysse virus infection and compensated liver disease in adults in Europe.
(Bio Valley) Smith-Magill syndrome drug was granted priority review by the FDA Vanda Pharmaceuticals recently announced that the FDA has accepted the company's submission of two applications for Smith-Magill syndrome, and granted priority review.
application includes a new drug application for Hetlioz capsule supplements and a new drug application for Hetlioz liquid preparation for the treatment of SMS adults and children, respectively.
(Bio Valley)